Proniosomes: the effective and efficient drug-carrier system

被引：19

作者：

Mittal, Swati ^{[1
]}

Chaudhary, Amit ^{[1
]}

Chaudhary, Anjali ^{[2
]}

Kumar, Ankit ^{[3
]}

机构：

[1] Abhilashi Univ, Sch Pharm, Mandi 175028, Himachal Prades, India

[2] Indian Pharmacopoeia Commiss, Ghaziabad 201002, Uttar Pradesh, India

[3] Swami Vivekanand Subharti Univ, Kharvel Subharti Coll Pharm, NH 58, Meerut 250005, Uttar Pradesh, India

来源：

THERAPEUTIC DELIVERY | 2020年 / 11卷 / 02期

关键词：

mechanism; nonionic; particle size; proniosomes; skin permeation; surfactant; targeting; topical; transdermal; vesicles; TRANSDERMAL DELIVERY; IN-VITRO; POTENTIAL TREATMENT; NIOSOMES; OPTIMIZATION; TACROLIMUS; VESICLES; ACID; GEL; ETHOSOMES(R);

D O I：

10.4155/tde-2019-0065

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Niosomes, liposomes and proniosomes are the most abundantly used vesicular systems for the transdermal delivery of drugs. Proniosomes are nonhydrated niosomes, which, upon hydration, form niosomes. Various researches have proved the advantages of proniosomes over the other conventional dosage forms currently available in the market. Proniosomes overcome physical stability problems involved with other vesicular systems such as leaking, fusion and aggregation. The stability and shelf life of proniosomes especially have been found to be much better and prolonged in comparison to other vesicular systems such as liposomes. The present review has been written in an effort to bring yet another viewpoint from a different angle and curated to compile the latest updates in this highly attractive delivery system from today's research point.

引用

页码：125 / 137

页数：13

共 70 条

[1] Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain [J].

Abdelbary, Ghada Ahmed ;

Aburahma, Mona Hassan .

JOURNAL OF LIPOSOME RESEARCH, 2015, 25 (02) :107-121

[2]

Agarwal S., 2004, INDIAN J PHARM SCI, V66, P121

[3]

Akhilesh D., 2012, International Journal of Pharmaceutical and Chemical Sciences, V1, P164

[4]

Ali N, 2012, IJRPC, V2, P2231

[5] Proniosomes as a drug carrier for transdermal delivery of ketorolac [J].

Alsarra, IA ;

Bosela, AA ;

Ahmed, SM ;

Mahrous, GM .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 59 (03) :485-490

[6] Proniosomes as a carrier system for transdermal delivery of tenoxicam [J].

Ammar, H. O. ;

Ghorab, M. ;

El-Nahhas, S. A. ;

Higazy, I. M. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 405 (1-2) :142-152

[7]

[Anonymous], 2019, TRANSDERMAL MARKET R

[8] Feasibility of proniosomes-based transdermal delivery of frusemide: Formulation optimization and pharmacotechnical evaluation [J].

Azeem, Adnan ;

Jain, Nilu ;

Iqbal, Zeenat ;

Ahmad, Farhan Jalees ;

Aqil, Mohammad ;

Talegaonkar, Sushama .

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2008, 13 (02) :155-163

[9] DLS and zeta potential - What they are and what they are not? [J].

Bhattacharjee, Sourav .

JOURNAL OF CONTROLLED RELEASE, 2016, 235 :337-351

[10]

Bouwstra J.A., 2010, OPEN DERMATOL J, V4, P10, DOI DOI 10.2174/1874372201004010010

← 1 2 3 4 5 6 7 →